健康价值评估中质量调整生命年的替代及优化方法介绍与比较  

Introduction and comparison of alternative and optimization methods for quality-adjusted life-year in health value assessment

作　　者：胡宏飞 周挺 李冯 马爱霞[1,2] HU Hong-fei;ZHOU Ting;LI Feng;MA Ai-xa(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China;Center for Pharmacoeconomics and Outcomes Research,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学国际医药商学院,南京211198 [2]中国药科大学药物经济学评价研究中心,南京211198

出　　处：《中国新药杂志》2024年第19期1969-1975,共7页Chinese Journal of New Drugs

摘　　要：质量调整生命年(quality-adjusted life-year, QALY)是药物经济学评价及价值评估中的重要健康结局指标,然而其背景理论和应用的条件假设近年来被学者质疑,受到挑战,如对老年人、残疾人或慢性疾病患者的歧视,无法准确反映患者偏好以及未考虑非健康获益等。因此,如何确定更优的健康结局指标成为当前亟待解决的问题。本研究通过介绍QALY替代和优化方法,全面阐述不同方法与QALY指标相比的优劣势,以期推动此类方法后续在我国开展相关研究和应用,为将来确定更为完善的健康结局指标提供方法学参考,促进我国卫生技术评估的应用与发展。Quality-adjusted life-year(QALY)is an important health outcome indicator in pharmacoeconomic evaluation and value assessment.However,the QALY theory and the assumptions in application have been challenged in recent years,such as discrimination against the elderly,the disabled,or the patients with chronic diseases,inability to accurately reflect patient preference,and the failure to consider non-health benefits.Therefore,the development of better health outcome indicators has become an urgent issue.This study introduces the alternative and optimization methods for QALY,and comprehensively compares the advantages and disadvantages of different methods with QALY.We aim to promote further research and application of these methods,to provide a methodological reference for identifying better health outcome indicators in the future,and to facilitate the application and development of health technology assessment in China.

关 键 词：价值评估 质量调整生命年 健康结局指标 药物经济学评价 卫生技术评估 替代或优化方法 

分 类 号：R95[医药卫生—药学]